决定异体 CAR T 细胞排斥与扩增的细胞和分子机制
Cellular and molecular mechanisms determining allogeneic CAR T cell rejection and expansion.
我们评估了11例接受单一批次cemacabtagene ansegedleucel(cema-cel)治疗的大B细胞淋巴瘤患者,cemacabtagene ansegedleucel是一种异体抗CD19 CAR T产品。
英文原题:The multifaceted roles of extracellular vesicles for therapeutic intervention with non-Hodgkin lymphoma.
细胞外囊泡(EVs)以多种方式参与癌症的发生发展。
细胞外囊泡(EV)可通过多种方式参与癌症发生发展。非霍奇金淋巴瘤(NHL)是成熟淋巴细胞来源的癌症,也是全球最常见的血液系统恶性肿瘤。NHL中最常见的类型弥漫性大B细胞淋巴瘤(DLBCL)主要采用化疗、自体干细胞移植(ASCT)和/或CAR-T 细胞疗法治疗。随着NHL进展和接受治疗,EV在影响患者结局方面发挥显著作用。这些作用可用于治疗干预,以改善NHL患者结局。本综述聚焦EV在NHL中的多方面作用,以及其指导患者照护的潜力。
Extracellular vesicles (EVs) contribute to the development of cancer in various ways. Non-Hodgkin lymphoma (NHL) is a cancer of mature lymphocytes and the most common hematological malignancy globally. The most common form of NHL, diffuse large B-cell lymphoma (DLBCL), is primarily treated with chemotherapy, autologous stem cell transplantation (ASCT), and/or chimeric antigen receptor T-cell (CAR-T) therapy. With NHL disease progression and its treatment, extracellular vesicles play remarkable roles in influencing outcomes. This finding can be utilized for therapeutic intervention to improve patient outcomes for NHL. This review focuses on the multifaceted roles of EVs with NHL and its potential for guiding patient care.
MEMBER ACCOUNT
登录成功会直接打开下一页。